罗莫索单抗对高骨折风险绝经后女性中轴与外周骨骼的影响:DXA与HR-pQCT真实世界证据
真实世界研究纳入28例高骨折风险绝经后女性,罗莫索单抗治疗12个月后腰椎和全髋面积骨密度显著增加,但桡骨和胫骨体积骨密度、微结构及强度未改善或恶化,且多数HR-pQCT变化与双膦酸盐治疗组无显著差异。
要点
- 罗莫索单抗治疗12个月显著提高腰椎和全髋aBMD,股骨颈无显著变化。
- 外周骨骼HR-pQCT显示桡骨和胫骨体积骨密度及微结构未改善或恶化。
- 多数外周骨骼变化与年龄匹配的双膦酸盐治疗女性无显著差异。
核心结论
- 罗莫索单抗治疗12个月后腰椎和全髋aBMD显著增加,但外周骨骼体积骨密度、微结构和强度未改善或恶化。
研究设计与样本
- 真实世界研究,纳入28例高骨折风险绝经后女性,在罗莫索单抗治疗开始前和12个月后行DXA和HR-pQCT检查。
- HR-pQCT结果与55例年龄匹配的近期骨折后接受双膦酸盐治疗的女性进行比较。
主要发现
- 腰椎aBMD较基线增加9.6%(IQR=6.6,15.7,p<0.001),全髋增加4.4±5.8%(p=0.001),股骨颈无显著变化。
- 桡骨远端总体体积骨密度下降2.4%([-4.3,-0.1],p=0.004),小梁骨体积骨密度下降1.7%([-3.5,0.5],p=0.013),小梁数、皮质厚度和皮质面积下降,小梁面积和分离度增加。
- 胫骨远端小梁数下降,小梁厚度、分离度和异质性增加,桡骨和胫骨刚度及失效载荷变化无统计学意义。
- 多数HR-pQCT变化与双膦酸盐组无显著差异。
关键数值与推荐
- 腰椎aBMD变化+9.6%(IQR=6.6,15.7,p<0.001),全髋+4.4±5.8%(p=0.001)。
- 桡骨远端总体体积骨密度变化-2.4%([-4.3,-0.1],p=0.004),小梁骨体积骨密度-1.7%([-3.5,0.5],p=0.013)。
临床怎么用
- 罗莫索单抗改善中轴骨aBMD,但对外周骨骼微结构和强度无明确获益,临床决策需结合外周骨折风险考量。
局限性
- 样本量小(罗莫索单抗组28例),非随机对照设计,外周骨骼变化与双膦酸盐组比较为观察性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Evidence on the effects of romosozumab mainly concerns axial aBMD. In 28 postmenopausal women, we found that spine and hip aBMD (DXA) significantly increased, while volumetric BMD, microarchitecture, and strength at the radius and tibia (HR-pQCT) remained unchanged or deteriorated. Most HR-pQCT changes did not differ from those in age-matched women on bisphosphonate treatment. PURPOSE: We assessed the effects of ROMO treatment on the axial skeleton using dual-energy X-ray absorptiometry (DXA) and on the peripheral skeleton using high-resolution peripheral quantitative CT (HR-pQCT) in real-world data of postmenopausal women at high fracture risk and compared HR-pQCT changes with those during bisphosphonate (BP) treatment. METHODS: As part of regular care in our hospital, DXA (lumbar spine, hip) and HR-pQCT (distal radius, distal tibia) were performed before the start (T0) and after 12 months (T1) of ROMO treatment. HR-pQCT results were compared with those in 55 age-matched women receiving BP treatment after a recent fracture. RESULTS: ROMO data were available of 28 women (72.4 ± 7.6 years, 67.9% treatment-naïve). At T0, areal bone mineral density (aBMD) T-scores were -2.3 ± 1.6 (lumbar spine), -2.1 ± 0.7 (total hip), and -2.7 ± 0.5 (femoral neck). At T1, aBMD was significantly higher than at T0 at the lumbar spine (+9.6% [IQR = 6.6,15.7], p < 0.001) and total hip (+4.4 ± 5.8%, p = 0.001) but not femoral neck. At the distal radius, a significant decrease was found in total (-2.4%, [-4.3,-0.1], p = 0.004) and trabecular (-1.7%, [-3.5,0.5], p = 0.013) volumetric BMD and in trabecular number, cortical thickness, and cortical area. Trabecular area and separation significantly increased. At the distal tibia, a significant change was found in trabecular number (decrease) and in trabecular thickness, separation, and heterogeneity (increase). Changes in radial and tibial stiffness and failure load were not significant. Most HR-pQCT changes did not significantly differ from those in the BP cohort. CONCLUSION: After 12 months of ROMO treatment, aBMD increased significantly at the lumbar spine and total hip, while volumetric BMD, microarchitecture, and strength at the peripheral skeleton did not change or deteriorated.
引用
- Bevers MSAM, Wyers CE, van Rietbergen B, et al. Effects of romosozumab on the peripheral and axial skeleton in postmenopausal women at high fracture risk: real-world evidence from DXA and HR-pQCT data. Osteoporos Int. 2026. PMID: 42711379. doi:10.1007/s00198-026-08148-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。